Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

Abstract

First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) Phase: PHASE1 Status: RECRUITING Conditions: T-cell Acute Lymphoblastic Leukemia; Lymphoblastic T-Cell Lymphoma Interventions: CD1a-CAR T

Keywords

Sources